

**Oxford Immunotec Global PLC**  
**Condensed consolidated statements of operations**  
**(unaudited)**

(in thousands, except share and per share data)	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
Revenue				
Product .....	\$ 6,613	\$ 5,887	\$ 13,735	\$ 12,712
Service .....	7,639	5,901	14,318	11,350
Total revenue .....	14,252	11,788	28,053	24,062
Cost of revenue				
Product .....	2,885	2,822	5,955	5,863
Service .....	3,617	3,171	7,202	6,142
Total cost of revenue .....	6,502	5,993	13,157	12,005
Gross profit.....	7,750	5,795	14,896	12,057
Operating expenses:				
Research and development .....	2,846	1,515	5,205	2,239
Sales and marketing.....	7,727	6,343	15,168	10,908
General and administrative.....	3,784	3,968	7,651	7,880
Total operating expenses .....	14,357	11,826	28,024	21,027
Loss from operations.....	(6,607)	(6,031)	(13,128)	(8,970)
Other income (expense):				
Interest expense, net .....	(19)	(28)	(34)	(63)
Foreign exchange losses .....	(674)	(262)	(509)	(407)
Other income .....	7	81	114	79
Loss before income taxes.....	(7,293)	(6,240)	(13,557)	(9,361)
Income tax expense (benefit) .....	1	(6)	48	26
Net loss.....	\$ (7,294)	\$ (6,234)	\$ (13,605)	\$ (9,387)
Net loss per share attributable to ordinary shareholders—basic and diluted .....	\$ (0.33)	\$ (0.36)	\$ (0.64)	\$ (0.54)
Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted .....	22,245,682	17,292,251	21,293,835	17,284,330

**Reconciliation of net loss to Adjusted EBITDA**  
**(unaudited)**

(in thousands)	<b>Three months ended June 30,</b>		<b>Six months ended June 30,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
Net loss.....	\$ (7,294)	\$ (6,234)	\$ (13,605)	\$ (9,387)
Income tax expense (benefit) .....	1	(6)	48	26
Interest expense, net .....	19	28	34	63
Depreciation and amortization .....	483	409	936	760
EBITDA .....	(6,791)	(5,803)	(12,587)	(8,538)
Reconciling items:				
Share-based compensation expense.....	713	760	1,588	1,025
Unrealized exchange (gains) losses .....	(459)	113	(615)	167
Loss on change in fair value of warrants .....	—	12	—	22
Change in fair value of contingent purchase price consideration.....	49	—	96	—
Adjusted EBITDA.....	\$ (6,488)	\$ (4,918)	\$ (11,518)	\$ (7,324)

**Oxford Immunotec Global PLC**  
**Condensed consolidated balance sheets**  
(unaudited)

(in thousands, except share and per share data)	<b>June 30, 2015</b>	<b>December 31, 2014</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents.....	\$ 90,370	\$ 50,165
Restricted cash .....	—	200
Accounts receivable, net .....	7,647	6,823
Inventory .....	5,470	6,425
Prepaid expenses and other assets.....	3,668	2,755
	107,155	66,368
Total current assets.....		
Restricted cash, non-current.....	192	192
Property and equipment, net .....	5,300	4,537
In-process research and development .....	2,209	2,399
Goodwill .....	46	50
Other intangible assets, net .....	300	273
Other assets .....	19	30
	\$ 115,221	\$ 73,849
<b>Liabilities and shareholders' equity</b>		
Current liabilities:		
Accounts payable .....	\$ 2,544	\$ 2,368
Accrued liabilities .....	5,843	7,070
Deferred income.....	2,720	1,993
Current portion of loans payable.....	125	137
	11,232	11,568
Total current liabilities .....		
Long-term portion of loans payable.....	385	454
Contingent purchase price consideration.....	1,219	1,218
	12,836	13,240
Total liabilities .....		
<b>Shareholders' equity:</b>		
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at June 30, 2015 and December 31, 2014, and 22,532,344 and 17,614,650 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively ..	242	192
Additional paid-in capital.....	242,128	186,816
Accumulated deficit .....	(135,434)	(121,829)
Accumulated other comprehensive loss .....	(4,551)	(4,570)
	102,385	60,609
Total shareholders' equity.....		
Total liabilities and shareholders' equity .....	\$ 115,221	\$ 73,849